PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34265431-13 2021 CONCLUSION: With or without brain metastasis, pembrolizumab plus platinum-based histology-specific chemotherapy improved clinical outcomes versus chemotherapy alone across all PD-L1 subgroups, including patients with PD-L1 tumor proportion score <1%, and had a manageable safety profile in patients with advanced NSCLC. Platinum 65-73 CD274 molecule Homo sapiens 176-181 34620772-5 2021 RECENT FINDINGS: PD-1/PD-L1 immune checkpoint inhibitors (ICIs) have demonstrated activity in the postplatinum and platinum-ineligible settings. Platinum 115-123 CD274 molecule Homo sapiens 22-27 34825576-3 2022 Results: The results showed platinum-based chemotherapy plus pembrolizumab or nivolumab and ipilimumab was associated with the best survival rates for patients with <1% PD-L1 expression, while only platinum-based chemotherapy plus pembrolizumab produced better survival than chemotherapy in patients with 1-49% PD-L1 expression. Platinum 28-36 CD274 molecule Homo sapiens 169-174 34825576-3 2022 Results: The results showed platinum-based chemotherapy plus pembrolizumab or nivolumab and ipilimumab was associated with the best survival rates for patients with <1% PD-L1 expression, while only platinum-based chemotherapy plus pembrolizumab produced better survival than chemotherapy in patients with 1-49% PD-L1 expression. Platinum 28-36 CD274 molecule Homo sapiens 311-316 34825576-4 2022 As for patients with >=50% PD-L1 expression, platinum-based chemotherapy plus pembrolizumab/atezolizumab and pembrolizumab/cemiplimab monotherapy were associated with better survival than chemotherapy. Platinum 45-53 CD274 molecule Homo sapiens 27-32 34791815-10 2022 CONCLUSIONS: The combination therapies, which were the platinum regimen + Pemb and the platinum regimen + Niv + Ipi, rather than ICI monotherapy were effective first-line agents for treating squamous NSCLC with low PD-L1 levels. Platinum 87-95 CD274 molecule Homo sapiens 215-220 34637432-4 2021 In recent years, the addition of anti-programmed death ligand 1 (PD-L1) inhibitors to frontline platinum-based chemotherapy in extensive-stage SCLC has improved survival, and combination chemoimmunotherapy is now approved as the standard of care. Platinum 96-104 CD274 molecule Homo sapiens 65-70 35129371-5 2022 Results: For the PD-L1 high population, a PD-1 inhibitor plus platinum-doublet provided significant progression-free survival (PFS) benefit versus bevacizumab. Platinum 62-70 CD274 molecule Homo sapiens 17-22 34734033-2 2021 The purpose of the present study was to estimate the cost-effectiveness of atezolizumab versus platinum-based chemotherapy for first-line treatment in metastatic NSCLC with high PD-L1 expression, from the perspective of US and Chinese payers. Platinum 95-103 CD274 molecule Homo sapiens 178-183 34646363-2 2021 Background: The addition of PD-L1 inhibitors to platinum-based chemotherapy (CT) has newly received United States Food and Drug Administration (FDA) approval in extensive stage-small cell lung cancer (ES-SCLC). Platinum 48-56 CD274 molecule Homo sapiens 28-33 34262873-1 2021 Objectives: Pembrolizumab plus platinum-based chemotherapy and pembrolizumab monotherapy (PM) both become standard of care in patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) greater than 50%. Platinum 31-39 CD274 molecule Homo sapiens 190-215 34262873-1 2021 Objectives: Pembrolizumab plus platinum-based chemotherapy and pembrolizumab monotherapy (PM) both become standard of care in patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) greater than 50%. Platinum 31-39 CD274 molecule Homo sapiens 217-222 35598358-5 2022 RESULTS: Platinum doublets and chemoimmunotherapy showed similar response rates (20-25%), disease control rates (80%) and median progression-free survival (mPFS, 7 months), which were longer compared to monochemotherapy (9%, 59%, 4.1 months), EGFR inhibitors (0%, 46%, 3.0) and PD-(L)1 inhibitors (0%, 30%, 2.1; p < 0.05). Platinum 9-17 CD274 molecule Homo sapiens 279-286 35598358-11 2022 CONCLUSIONS: Platinum doublets and chemoimmunotherapy have the highest activity with ORR of 20-25% and mPFS of approximately 7 months, regardless of the cytotoxic partner, while PD-(L)1 inhibitors show limited efficacy. Platinum 13-21 CD274 molecule Homo sapiens 178-185 35170879-11 2022 Platinum-based regimens combined with targeted therapies (Bev, PARPi, and PD-1/PD-L1 inhibitor) also improve the pCR rate beyond that with AT alone, but this benefit is accompanied by greater toxicity. Platinum 0-8 CD274 molecule Homo sapiens 79-84 35042068-1 2022 BACKGROUND: Prior durvalumab (anti-PD-L1 agent) studies in platinum-refractory metastatic urothelial carcinoma evaluated a dose of 10 mg/kg administered every two weeks. Platinum 59-67 CD274 molecule Homo sapiens 35-40 33382454-0 2021 Efficacy and safety of PD1/PDL1 blockade with platinum-based chemotherapy for extensive small cell lung cancer: a pooled analysis of randomized trials. Platinum 46-54 CD274 molecule Homo sapiens 27-31 33545805-0 2021 Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report. Platinum 74-82 CD274 molecule Homo sapiens 5-10 32954856-6 2021 On the one hand, the positive effects of platinum-based chemotherapy on immunomodulation can be harnessed to increase the sensitivity of tumor cells to PD-1/PD-L1 inhibitors. Platinum 41-49 CD274 molecule Homo sapiens 157-162 32954856-7 2021 On the other hand, platinum-based chemotherapy may upregulate PD-L1 expression in tumor tissue and exert a negative immunomodulatory effect, which can be counteracted by PD-1/PD-L1 inhibitors through their action pathway. Platinum 19-27 CD274 molecule Homo sapiens 62-67 32954856-7 2021 On the other hand, platinum-based chemotherapy may upregulate PD-L1 expression in tumor tissue and exert a negative immunomodulatory effect, which can be counteracted by PD-1/PD-L1 inhibitors through their action pathway. Platinum 19-27 CD274 molecule Homo sapiens 175-180 33687763-3 2021 Both trials demonstrated an improvement in overall survival (OS) with anti-PD-L1 antibodies when added to platinum-based chemotherapy as compared to chemotherapy alone. Platinum 106-114 CD274 molecule Homo sapiens 75-80 33930176-21 2021 Single-agent ICI In the PD-L1 expression >= 50% group single-agent ICI probably improved OS compared to platinum-based chemotherapy (hazard ratio (HR) 0.68, 95% confidence interval (CI) 0.60 to 0.76, 6 RCTs, 2111 participants, moderate-certainty evidence). Platinum 104-112 CD274 molecule Homo sapiens 24-29 33930176-26 2021 More information about efficacy of single-agent ICI compared to platinum-based chemotherapy according to the level of PD-L1 expression and to TMB status or specific clinical characteristics is available in the full text. Platinum 64-72 CD274 molecule Homo sapiens 118-123 33894335-6 2021 RESULTS: After median follow-up of 31.0 months, pembrolizumab plus pemetrexed-platinum continued to improve OS (hazard ratio [HR], 0.56; 95% CI, 0.46-0.69), and PFS (HR, 0.49; 95% CI, 0.41-0.59) over placebo plus pemetrexed-platinum regardless of PD-L1 expression. Platinum 78-86 CD274 molecule Homo sapiens 247-252 33839362-2 2021 However, when used in combination with platinum-based chemotherapy, these PD-L1 inhibitors only improve overall survival by 2-3 months. Platinum 39-47 CD274 molecule Homo sapiens 74-79 33869015-3 2021 Our objective was to compare the clinical efficacy and safety of anti-PD-1/PD-L1 therapies in platinum-resistant UC patients. Platinum 94-102 CD274 molecule Homo sapiens 75-80 32361873-5 2021 More recently, several anti-PD-L1 and anti-PD-1 antibodies have shown promising activity in the first-line and post-platinum setting; however, immunotherapy remains ineffective in most patients. Platinum 116-124 CD274 molecule Homo sapiens 28-33 33523301-2 2021 METHODS: We investigated 1181 Korean patients with programmed death-1 ligand 1 (PD-L1)-positive [tumor proportion score (TPS) >= 10% by the SP263 assay or >= 50% by the 22C3 assay] R/M-NSCLC treated with pembrolizumab or nivolumab after failure of platinum-based chemotherapy. Platinum 248-256 CD274 molecule Homo sapiens 80-85 33073546-1 2020 INTRODUCTION: Platinum-based chemotherapy is currently the most frequently applied first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) without targetable mutations or high PD-L1 expression. Platinum 14-22 CD274 molecule Homo sapiens 203-208 32897000-0 2020 Multispecific Platinum(IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX-2 and PD-L1. Platinum 14-22 CD274 molecule Homo sapiens 136-141 33316104-22 2020 Single-agent ICI In the PD-L1 expression >= 50% group single-agent ICI probably improved OS compared to platinum-based chemotherapy (hazard ratio (HR) 0.68, 95% confidence interval (CI) 0.60 to 0.76, 6 RCTs, 2111 participants, moderate-certainty evidence). Platinum 104-112 CD274 molecule Homo sapiens 24-29 33316104-27 2020 More information about efficacy of single-agent ICI compared to platinum-based chemotherapy according to the level of PD-L1 expression and to TMB status or specific clinical characteristics is available in the full text. Platinum 64-72 CD274 molecule Homo sapiens 118-123 33569311-9 2021 The logistic model analyzing the association between decreased PD-L1 expression on CTCs after RRx-001 and response to reintroduced platinum doublet had an approximate 92.8% accuracy in its prediction of clinical benefit. Platinum 131-139 CD274 molecule Homo sapiens 63-68 33569311-11 2021 Conclusions: These results suggest that PD-L1 expression on CTCs decreased after RRx-001 was significantly correlated with response to reintroduced platinum-based doublet therapy. Platinum 148-156 CD274 molecule Homo sapiens 40-45 32552295-12 2020 CONCLUSIONS: A validated 5-factor model has satisfactory prognostic performance for survival across 3 PD-L1 inhibitors to treat mUC post-platinum and may assist in stratification, interpreting and designing trials incorporating PD-1/PD-L1 inhibitors in the post-platinum setting. Platinum 137-145 CD274 molecule Homo sapiens 102-107 32552295-12 2020 CONCLUSIONS: A validated 5-factor model has satisfactory prognostic performance for survival across 3 PD-L1 inhibitors to treat mUC post-platinum and may assist in stratification, interpreting and designing trials incorporating PD-1/PD-L1 inhibitors in the post-platinum setting. Platinum 262-270 CD274 molecule Homo sapiens 102-107 33037118-1 2020 BACKGROUND: Anti-programmed cell death ligand 1 (PD-L1)/programmed cell death 1 antibodies have shown clinical activity in platinum-treated metastatic urothelial carcinoma, resulting in regulatory approval of several agents, including avelumab (anti-PD-L1). Platinum 123-131 CD274 molecule Homo sapiens 12-47 32914866-1 2020 BACKGROUND: Pembrolizumab plus platinum-based chemotherapy has demonstrated improved clinical outcomes over chemotherapy alone in patients with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC), regardless of tumor programmed death ligand 1 (PD-L1) expression. Platinum 31-39 CD274 molecule Homo sapiens 241-266 32914866-1 2020 BACKGROUND: Pembrolizumab plus platinum-based chemotherapy has demonstrated improved clinical outcomes over chemotherapy alone in patients with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC), regardless of tumor programmed death ligand 1 (PD-L1) expression. Platinum 31-39 CD274 molecule Homo sapiens 268-273 33037118-1 2020 BACKGROUND: Anti-programmed cell death ligand 1 (PD-L1)/programmed cell death 1 antibodies have shown clinical activity in platinum-treated metastatic urothelial carcinoma, resulting in regulatory approval of several agents, including avelumab (anti-PD-L1). Platinum 123-131 CD274 molecule Homo sapiens 49-54 33037118-1 2020 BACKGROUND: Anti-programmed cell death ligand 1 (PD-L1)/programmed cell death 1 antibodies have shown clinical activity in platinum-treated metastatic urothelial carcinoma, resulting in regulatory approval of several agents, including avelumab (anti-PD-L1). Platinum 123-131 CD274 molecule Homo sapiens 250-255 32706170-5 2020 Conversely, an anti-PD-L1 antibody synergistic effect on platinum compounds was assessed in a preclinical study, which was reinforced by clinical data. Platinum 57-65 CD274 molecule Homo sapiens 20-25 32966352-2 2020 In the advanced stage of non-small cell non-squamous lung cancer, without actionable mutation, the immune monotherapy or combination treatment with platinum based chemotherapy is a new standard of care depending on PD-L1 status. Platinum 148-156 CD274 molecule Homo sapiens 215-220 32966352-9 2020 In extensive stage small cell lung cancer the platinum-etoposide treatment with PD-L1 inhibitor is a new standard, but we do not have any effective biomarkers yet. Platinum 46-54 CD274 molecule Homo sapiens 80-85 32921017-0 2020 [Influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer who received platinum-based adjuvant chemotherapy]. Platinum 143-151 CD274 molecule Homo sapiens 35-60 32921017-0 2020 [Influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer who received platinum-based adjuvant chemotherapy]. Platinum 143-151 CD274 molecule Homo sapiens 62-67 32921017-1 2020 Objective: The aim of present study was to investigate the influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer (NSCLC) who received platinum-based adjuvant chemotherapy. Platinum 209-217 CD274 molecule Homo sapiens 93-118 32921017-1 2020 Objective: The aim of present study was to investigate the influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer (NSCLC) who received platinum-based adjuvant chemotherapy. Platinum 209-217 CD274 molecule Homo sapiens 120-125 32921017-16 2020 Conclusion: The prognosis of patients with postoperative non-small cell lung cancer who received platinum-based adjuvant chemotherapy is influenced by -1813G>C polymorphism of PD-L1 gene. Platinum 97-105 CD274 molecule Homo sapiens 176-181 32646443-4 2020 In inoperable Stage III NSCLC, consolidation immune checkpoint inhibition with the PD-L1 inhibitor durvalumab after completion of concurrent platinum-based chemoradiotherapy resulted in remarkable improvement of progression-free and overall survival. Platinum 141-149 CD274 molecule Homo sapiens 83-88 32801904-1 2020 Purpose: This study was done to investigate the influence of PDL1-gene polymorphism on the prognosis and safety of postoperative patients with non-small cell lung cancer (NSCLC) who had received platinum-based adjuvant chemotherapy. Platinum 195-203 CD274 molecule Homo sapiens 61-65 32801904-14 2020 Conclusion: The prognosis of postoperative patients with NSCLC who have received platinum-based adjuvant chemotherapy may be influenced by the rs822336 polymorphism through mediation of the mRNA expression of PDL1. Platinum 81-89 CD274 molecule Homo sapiens 209-213 32670420-10 2020 Conclusion: PD-1/PD-L1 inhibitor plus nab-paclitaxel resulted in significantly longer OS and higher response versus ICI single agent in metastatic NSCLC patients who have progressed after platinum-based chemotherapy. Platinum 188-196 CD274 molecule Homo sapiens 17-22 32922610-9 2020 PD-L1 rs2890658 C>A and rs822336 G>C are related to the prognoses of patients receiving platinum-based chemotherapy. Platinum 88-96 CD274 molecule Homo sapiens 0-5 32720019-3 2020 This mono-immunotherapy approach for high PD-L1 metastatic NSCLC is associated with improved overall survival (OS) and radiological responses (RR) with lesser toxicity as compared with conventional platinum doublet chemotherapy for both non-squamous and squamous histological types.However, majority of NSCLC patients either have no or low expression of PD-L1 (< 50%) and such patients derive greater benefit from a combination of PD-1/PD-L1 ICIs with platinum doublet chemotherapy as compared with chemotherapy alone. Platinum 452-460 CD274 molecule Homo sapiens 42-47 32635291-9 2020 In conclusion, PD-(L)1 blockade added to standard platinum-based chemotherapy significantly improved PFS, OS, and ORR in the up-front treatment of advanced NSCLC. Platinum 50-58 CD274 molecule Homo sapiens 15-22 32078962-1 2020 PURPOSE: The combination of an anti-programmed death 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) monoclonal antibody with platinum-based chemotherapy can improve outcomes for patients with advanced non-small-cell lung cancer (NSCLC) or small-cell lung cancer (SCLC) compared with chemotherapy alone. Platinum 129-137 CD274 molecule Homo sapiens 97-102 32150489-1 2020 PURPOSE: In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression. Platinum 66-74 CD274 molecule Homo sapiens 301-326 32150489-1 2020 PURPOSE: In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression. Platinum 66-74 CD274 molecule Homo sapiens 328-333 32527769-7 2020 PD-L1-positive expression was observed in 50.5% of patients and associated with more advanced stage (p=0.047), more aggressive histologic subtype (p=0.001), and platinum sensitivity defined by increasing treatment-free interval from first platinum-based chemotherapy to next systemic treatment (p=0.027). Platinum 161-169 CD274 molecule Homo sapiens 0-5 32527769-7 2020 PD-L1-positive expression was observed in 50.5% of patients and associated with more advanced stage (p=0.047), more aggressive histologic subtype (p=0.001), and platinum sensitivity defined by increasing treatment-free interval from first platinum-based chemotherapy to next systemic treatment (p=0.027). Platinum 239-247 CD274 molecule Homo sapiens 0-5 32078962-7 2020 Immune-mediated AEs and infusion reactions occurred more commonly in patients who received anti-PD-(L)1 immunotherapy with platinum-based chemotherapy compared with chemotherapy alone; however, there was no evidence of unexpected or unanticipated toxicity with these combinations. Platinum 123-131 CD274 molecule Homo sapiens 96-103 31930091-2 2019 Due to restrictions by the FDA and EMA first-line treatment with Atezolizumab and Pembrolizumab in platinum-ineligible patients requires immunohistochemical PD-L1 testing. Platinum 99-107 CD274 molecule Homo sapiens 157-162 31853007-0 2020 PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma. Platinum 25-33 CD274 molecule Homo sapiens 0-5 31966052-6 2020 A total of 26 patients exhibited highly methylated PD-L1; in this group, the median progression-free survival time of patients receiving platinum/fluorouracil chemotherapy was 4.2 months longer than those receiving paclitaxel/fluorouracil chemotherapy, and the risk of disease progression in patients receiving paclitaxel/fluorouracil chemotherapy was 5.009 times higher compared with patients who received platinum/fluorouracil chemotherapy. Platinum 137-145 CD274 molecule Homo sapiens 51-56 31966052-6 2020 A total of 26 patients exhibited highly methylated PD-L1; in this group, the median progression-free survival time of patients receiving platinum/fluorouracil chemotherapy was 4.2 months longer than those receiving paclitaxel/fluorouracil chemotherapy, and the risk of disease progression in patients receiving paclitaxel/fluorouracil chemotherapy was 5.009 times higher compared with patients who received platinum/fluorouracil chemotherapy. Platinum 407-415 CD274 molecule Homo sapiens 51-56 31907140-1 2019 Bladder urothelial carcinoma(BUC)is a common malignant tumor in the urinary system.Pt-based chemotherapy has long been a standard therapeutic method for resectable or metastatic BUC,but with poor outcomes.Immune checkpoint inhibitors specific to programmed death 1(PD-1)/programmed death-ligand 1(PD-L1)and cytotoxic T lymphocyte-associated protein 4(CTLA-4)pathways have shown significant antitumor activities,safety,and enduring reactivity in clinical trials,thus creating a new epoch for the treatment of advanced-stage BUC.This article reviews the relationships of BUC with PD-1/PD-L1 and CTLA-4 pathways,as demonstrated in clinical trials.In particular,the authors elucidate the clinical studies on the application of immune checkpoint inhibitors in different BUC stages and their optimal combining strategies,with an attempt to improve the clinical use of immune inhibitors for BUC treatment. Platinum 83-85 CD274 molecule Homo sapiens 297-302 31612261-4 2019 RESULTS: The Keynote-048 study showed an improvement in overall survival with pembrolizumab monotherapy for patients with measurable programmed cell death ligand 1 (PD-L1) expression according to the combined positive score (CPS), and for the whole cohort with the combination of pembrolizumab and platin/5-fluorouracil (FU). Platinum 298-304 CD274 molecule Homo sapiens 165-170 31867425-0 2019 PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis. Platinum 73-81 CD274 molecule Homo sapiens 0-5 31200951-1 2019 CONTEXT: Several anti-programmed death-1 (anti-PD-1) and anti-programmed death ligand-1 (anti-PD-L1) antibodies have been approved by regulatory authorities for treatment of platinum-resistant metastatic urothelial cancer (mUC). Platinum 174-182 CD274 molecule Homo sapiens 94-99 31200951-3 2019 OBJECTIVE: To determine the restricted mean survival time (RMST) of patients with platinum-resistant mUC treated with PD-1/PD-L1 inhibitors and to compare RMSTs in patients treated with PD-1 versus PD-L1 inhibitors. Platinum 82-90 CD274 molecule Homo sapiens 123-128 31200951-4 2019 EVIDENCE ACQUISITION: We searched for phase 1, 2, and 3 clinical trials that assessed PD-1 or PD-L1 inhibition for patients with platinum-resistant mUC. Platinum 129-137 CD274 molecule Homo sapiens 94-99 31852114-6 2019 The incidence rate of all-grade of hypothyroidism was lower in PD-1/PD-L1 inhibitor subgroup compared to chemotherapy (OR = 22.62, 95%CI:9.79-52.25), while the similar result was seen in another treatment regimen (PD-1 + platinum-based chemotherapy vs platinum-based chemotherapy) (OR = 2.93, 95%CI: [2.08, 4.11). Platinum 221-229 CD274 molecule Homo sapiens 68-73 31852114-6 2019 The incidence rate of all-grade of hypothyroidism was lower in PD-1/PD-L1 inhibitor subgroup compared to chemotherapy (OR = 22.62, 95%CI:9.79-52.25), while the similar result was seen in another treatment regimen (PD-1 + platinum-based chemotherapy vs platinum-based chemotherapy) (OR = 2.93, 95%CI: [2.08, 4.11). Platinum 252-260 CD274 molecule Homo sapiens 68-73 31671550-2 2019 Nearly 10 years after the approval of cetuximab, anti-PD1/PD-L1 checkpoint inhibitors are the first drugs that have shown any survival benefit for the treatment on platinum-refractory recurrent/metastatic (R/M) HNSCC. Platinum 164-172 CD274 molecule Homo sapiens 58-63 30428640-0 2019 Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer. Platinum 10-18 CD274 molecule Homo sapiens 41-46 31262689-2 2019 In this study, we investigated whether PD-L1 expression is affected by platinum-based chemotherapy. Platinum 71-79 CD274 molecule Homo sapiens 39-44 30374610-4 2019 The PD-1 and PD-L1 inhibitors provide a new and effective treatment option for patients with UC, particularly for patients with recurrence after platinum-based therapy and those who are ineligible for cisplatin. Platinum 145-153 CD274 molecule Homo sapiens 13-18 31173242-0 2019 Effect of platinum-based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death-1 ligand 1 and HLA class I in non-small cell lung cancer. Platinum 10-18 CD274 molecule Homo sapiens 100-132 31435660-1 2019 BACKGROUND: In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on >=50% of tumor cells, first-line treatment with the PD-1 inhibitor pembrolizumab improves survival compared with platinum-doublet chemotherapy. Platinum 209-217 CD274 molecule Homo sapiens 48-73 31435660-1 2019 BACKGROUND: In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on >=50% of tumor cells, first-line treatment with the PD-1 inhibitor pembrolizumab improves survival compared with platinum-doublet chemotherapy. Platinum 209-217 CD274 molecule Homo sapiens 75-80 31573752-7 2019 For platinum-sensitive or first-line patients, pembrolizumab monotherapy (patients with PD-L1 Combined Positive Score >= 20) or pembrolizumab-platinum-fluorouracil improved overall survival vs the EXTREME (cetuximab-platinum-fluorouracil). Platinum 4-12 CD274 molecule Homo sapiens 88-93 30428640-2 2019 We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression and its clinical implications. Platinum 26-34 CD274 molecule Homo sapiens 63-68 30428640-10 2019 CONCLUSION: Tumor PD-L1 expression increased after platinum-based NACT in a significant proportion of patients with NSCLC. Platinum 51-59 CD274 molecule Homo sapiens 18-23 30482243-2 2018 Based on the mechanisms of CSCC carcinogenesis has been postulated that these tumors may be amenable to PD-1/PD-L1 blockade.This case illustrates a patient with CSCC with nodal involvement and pulmonary metastases, refractory to two lines of platinum-based regimens and salvage surgery, for whom treatment with nivolumab was recommended. Platinum 242-250 CD274 molecule Homo sapiens 109-114 30851984-1 2019 Analysis of the IMvigor 210 trials involving patients with platinum-refractory or cisplatin-ineligible urothelial carcinoma who were treated with the PD-L1 inhibitor atezolizumab identified a resistance signature as an immune biomarker. Platinum 59-67 CD274 molecule Homo sapiens 150-155 30954906-4 2019 Of note, the presence of both negative PD-L1 expression and low TMB may identify a subgroup of patients who has little benefit from immunotherapy combinations and for whom the best treatment option may still be platinum-based chemotherapy. Platinum 211-219 CD274 molecule Homo sapiens 39-44 30664989-1 2019 INTRODUCTION: This randomized phase II trial aimed at evaluating the engineered programmed cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line platinum-etoposide chemotherapy. Platinum 178-186 CD274 molecule Homo sapiens 80-110 31130676-2 2019 Previously it was reported that platinum-based chemotherapy may change PD-L1 expression in solid cancers. Platinum 32-40 CD274 molecule Homo sapiens 71-76 30565086-8 2019 In cases of progression after platinum-based therapy, PD-1/PD-L1 inhibitors are standard alternatives. Platinum 30-38 CD274 molecule Homo sapiens 59-64 30280635-1 2018 BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on >=50% of tumor cells). Platinum 103-111 CD274 molecule Homo sapiens 194-199 30049372-0 2018 Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer. Platinum 38-46 CD274 molecule Homo sapiens 133-138 30466712-10 2018 Checkpoint inhibitors such as anti-PD-1 and anti-PD-L1 antibodies, were shown to significantly improve disease free survival and overall survival after failure of platinum-based chemotherapy. Platinum 163-171 CD274 molecule Homo sapiens 49-54 29650143-3 2018 The introduction of anti-programmed cell death protein 1/programmed death-ligand 1(PD1/PD-L1) checkpoint inhibitors has redefined the therapeutic landscape for platinum-resistant urothelial cancers; their clinical efficacy and favorable toxicity render these agents attractive therapeutic options either as monotherapy or in combination with other agents in earlier disease states, including muscle-invasive disease. Platinum 160-168 CD274 molecule Homo sapiens 87-92 29325739-8 2018 Anti-PD-1/PD-L1 antibodies have shown favorable clinical activity and tolerability in patients with metastatic urothelial carcinoma refractory to platinum-based therapy or who are ineligible for cisplatin. Platinum 146-154 CD274 molecule Homo sapiens 10-15 29644490-3 2018 RECENT FINDINGS: Since May 2016, five different agents targeting the PD-1/PD-L1 pathway (atezolizumab, pembrolizumab, nivolumab, avelumab, durvalumab) have received FDA approval for the treatment of aUC in the platinum-refractory setting, while pembrolizumab and atezolizumab are FDA-approved for cisplatin-ineligible patients in the first-line setting. Platinum 210-218 CD274 molecule Homo sapiens 74-79 29472240-1 2018 Researchers have presented a new model that uses six readily available clinical factors to predict whether a patient with advanced bladder cancer who has already received platinum chemotherapy will respond to treatment with the PD-L1 inhibitor atezolizumab. Platinum 171-179 CD274 molecule Homo sapiens 228-233 29209522-7 2017 One option for patients with PD-L1 expression lower than 50% may be the combination of ICI with platinum-based chemotherapy or with ICIs against different targets. Platinum 96-104 CD274 molecule Homo sapiens 29-34 29517083-6 2017 Currently, the only FDA-approved indication for the anti-PD-L1 monoclonal antibody durvalumab (MEDI-4736) is locally advanced or metastatic urothelial carcinoma that has progressed during or following platinum-based chemotherapy within 12 months of treatment. Platinum 201-209 CD274 molecule Homo sapiens 57-62 28994323-3 2017 Atezolizumab is an engineered humanized anti-PD-L1 monoclonal antibody that inhibits PD-L1 binding to PD-1 and B7.1, enhancing immune-mediated tumor killing and is currently approved as second-line treatment after failure of platinum-based chemotherapy as well as first-line in cisplatin-ineligible patients. Platinum 225-233 CD274 molecule Homo sapiens 45-50 28994323-3 2017 Atezolizumab is an engineered humanized anti-PD-L1 monoclonal antibody that inhibits PD-L1 binding to PD-1 and B7.1, enhancing immune-mediated tumor killing and is currently approved as second-line treatment after failure of platinum-based chemotherapy as well as first-line in cisplatin-ineligible patients. Platinum 225-233 CD274 molecule Homo sapiens 85-90 29027395-5 2017 RESULTS: Overall, high PD-L1 expression (PD-L1(high)) was observed in 44.7% (55/123) of OCCC patients, and was strongly associated with advanced stages (p=0.020), positive ascitic fluid (p=0.016), platinum-resistant (PR) disease (p=0.045), and recurrence (p=0.038). Platinum 197-205 CD274 molecule Homo sapiens 23-28 29027395-5 2017 RESULTS: Overall, high PD-L1 expression (PD-L1(high)) was observed in 44.7% (55/123) of OCCC patients, and was strongly associated with advanced stages (p=0.020), positive ascitic fluid (p=0.016), platinum-resistant (PR) disease (p=0.045), and recurrence (p=0.038). Platinum 197-205 CD274 molecule Homo sapiens 41-46 28391420-10 2017 At progression despite available TKIs, we use pemetrexed-based platinum doublet chemotherapy or immunotherapy if the tumor has high expression of PDL-1. Platinum 63-71 CD274 molecule Homo sapiens 146-151 28534248-4 2017 In those who have progressed after receiving platinum-based chemotherapy in the first-line, multiple PD-1/PD-L1 agents are available and currently approved, including nivolumab, pembrolizumab, and atezolizumab. Platinum 45-53 CD274 molecule Homo sapiens 106-111 27329924-1 2016 Results from a phase II study indicate that the PD-L1 inhibitor atezolizumab, recently approved for advanced bladder cancer that"s refractory to standard platinum chemotherapy, is effective as first-line therapy for this disease. Platinum 154-162 CD274 molecule Homo sapiens 48-53 28187748-11 2017 AURKA and PD-L1 correlated with the resistance to platinum-based chemotherapy in CCC patients (P = 0.043, 0.028, respectively) while no similar results were observed in HGSC patients. Platinum 50-58 CD274 molecule Homo sapiens 10-15 27920140-2 2016 It is the first PD-L1 inhibitor approved for use in patients with metastatic non-small cell lung cancer that has advanced in spite of treatment with platinum-based chemotherapy. Platinum 149-157 CD274 molecule Homo sapiens 16-21 27713639-3 2016 It has been approved by the US Food and Drug Administration for the treatment of patients with metastatic NSCLC, whose tumors express PD-1 ligand 1 (PD-L1), with disease progression on or after platinum-containing chemotherapy. Platinum 194-202 CD274 molecule Homo sapiens 149-154